Section Arrow
TRML.NASDAQ
- Tourmaline Bio
Quotes are at least 15-min delayed:2025/07/21 06:53 EDT
Pre Market
Last
 --
-- (--)
Bid
17.35
Ask
29.56
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 18.48
-0.12 (-0.65%)
Day High 
19.055 
Prev. Close
18.6 
1-M High
19.22 
Volume 
120.34K 
Bid
17.35
Ask
29.56
Day Low
18.265 
Open
18.83 
1-M Low
15.45 
Market Cap 
477.81M 
Currency USD 
P/E -- 
%Yield 55.58 
10-SMA 17.59 
20-SMA 17.08 
50-SMA 17.01 
52-W High 29.7883 
52-W Low 11.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.23/-3.79
Enterprise Value
477.82M
Balance Sheet
Book Value Per Share
10.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.975 -0.305 -13.38%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.1 -0.975 -6.93%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.26 +0.42 +7.19%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.07 +0.15 +2.53%
Quotes are at least 15-min delayed:2025/07/21 06:53 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.